Loading...

Hutchison China MediTech

OTCPK:HNCM.F
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
HNCM.F
OTCPK
£3B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People’s Republic of China and Hong Kong. The last earnings update was 11 days ago. More info.


Add to Portfolio Compare Print
HNCM.F Share Price and Events
7 Day Returns
0%
OTCPK:HNCM.F
-0.5%
US Pharmaceuticals
0.5%
US Market
1 Year Returns
-
OTCPK:HNCM.F
6%
US Pharmaceuticals
0.8%
US Market
HNCM.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Hutchison China MediTech (HNCM.F) 0% 0% - - - 341.6%
US Pharmaceuticals -0.5% 0% -2.9% 6% 9.1% 14%
US Market 0.5% -0.1% 1% 0.8% 37.5% 37.5%
1 Year Return vs Industry and Market
  • No trading data on HNCM.F.
  • No trading data on HNCM.F.
Price Volatility
HNCM.F
Industry
5yr Volatility vs Market

Value

 Is Hutchison China MediTech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Hutchison China MediTech to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Hutchison China MediTech.

OTCPK:HNCM.F Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.1%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OTCPK:HNCM.F
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6.7%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.64 (1 + (1- 25%) (0.93%))
0.761
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.8 * 6.65%)
8.05%

Discounted Cash Flow Calculation for OTCPK:HNCM.F using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Hutchison China MediTech is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

OTCPK:HNCM.F DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.05%)
2019 -165.50 Analyst x1 -153.17
2020 -139.50 Analyst x1 -119.49
2021 152.02 Analyst x1 120.51
2022 297.44 Analyst x1 218.23
2023 509.06 Analyst x1 345.65
2024 700.35 Est @ 37.58% 440.11
2025 890.30 Est @ 27.12% 517.80
2026 1,066.63 Est @ 19.81% 574.13
2027 1,223.23 Est @ 14.68% 609.38
2028 1,358.97 Est @ 11.1% 626.56
Present value of next 10 years cash flows $3,179.73
OTCPK:HNCM.F DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $1,358.97 × (1 + 2.73%) ÷ (8.05% – 2.73%)
$26,241.99
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $26,241.99 ÷ (1 + 8.05%)10
$12,098.99
OTCPK:HNCM.F Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $3,179.73 + $12,098.99
$15,278.71
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $15,278.71 / 665.64
$1.58
OTCPK:HNCM.F Discount to Share Price
Calculation Result
Exchange Rate USD/GBP
(Reporting currency to currency of AIM:HCM)
0.793
Value per Share
(GBP)
= Value per Share in USD x Exchange Rate (USD/GBP)
= $22.95 x 0.793
£18.21
Value per share (USD) From above. $263.95
Current discount Discount to share price of $61.60
= -1 x ($61.60 - $263.95) / $263.95
76.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Hutchison China MediTech is available for.
Intrinsic value
>50%
Share price is $61.6 vs Future cash flow value of $263.95
Current Discount Checks
For Hutchison China MediTech to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Hutchison China MediTech's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Hutchison China MediTech's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Hutchison China MediTech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Hutchison China MediTech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:HNCM.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.12
AIM:HCM Share Price ** AIM (2019-04-04) in GBP £4.25
AIM:HCM Share Price converted to USD reporting currency Exchange rate (GBP/ USD) 1.261 $5.36
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 17.22x
United States of America Market PE Ratio Median Figure of 3,094 Publicly-Listed Companies 17.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Hutchison China MediTech.

OTCPK:HNCM.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:HCM Share Price ÷ EPS (both in USD)

= 5.36 ÷ -0.12

-42.92x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Hutchison China MediTech is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Hutchison China MediTech is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Hutchison China MediTech's expected growth come at a high price?
Raw Data
OTCPK:HNCM.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -42.92x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
47.5%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.55x
United States of America Market PEG Ratio Median Figure of 2,125 Publicly-Listed Companies 1.52x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Hutchison China MediTech, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Hutchison China MediTech's assets?
Raw Data
OTCPK:HNCM.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.56
AIM:HCM Share Price * AIM (2019-04-04) in GBP £4.25
AIM:HCM Share Price converted to USD reporting currency Exchange rate (GBP/ USD) 1.261 $5.36
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 183 Publicly-Listed Pharmaceuticals Companies 3.26x
United States of America Market PB Ratio Median Figure of 5,244 Publicly-Listed Companies 1.79x
OTCPK:HNCM.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:HCM Share Price ÷ Book Value per Share (both in USD)

= 5.36 ÷ 0.56

9.49x

* Primary Listing of Hutchison China MediTech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Hutchison China MediTech is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Hutchison China MediTech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Hutchison China MediTech has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Hutchison China MediTech expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Hutchison China MediTech expected to grow at an attractive rate?
  • Hutchison China MediTech's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Hutchison China MediTech's earnings growth is expected to exceed the United States of America market average.
  • Hutchison China MediTech's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
OTCPK:HNCM.F Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:HNCM.F Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 47.5%
OTCPK:HNCM.F Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 26.3%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 14.7%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.3%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:HNCM.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:HNCM.F Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 585 -39 100 2
2022-12-31 411 -81 -18 2
2021-12-31 266 -124 -121 3
2020-12-31 215 -146 -148 5
2019-12-31 187 -133 -149 6
OTCPK:HNCM.F Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 214 -31 -83
2018-12-31 214 -33 -75
2018-09-30 215 -40 -68
2018-06-30 217 -47 -61
2018-03-31 230 -49 -39
2017-12-31 241 -9 -27
2017-09-30 240 -4 -7
2017-06-30 238 1 13
2017-03-31 227 -4 12
2016-12-31 216 -10 12
2016-09-30 200 2 38
2016-06-30 200 -1 -8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Hutchison China MediTech's earnings are expected to grow significantly at over 20% yearly.
  • Hutchison China MediTech's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:HNCM.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Hutchison China MediTech Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:HNCM.F Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 -0.25 -0.25 -0.25 1.00
2020-12-31 -0.25 -0.25 -0.25 2.00
2019-12-31 -0.25 -0.25 -0.26 2.00
OTCPK:HNCM.F Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.12
2018-12-31 -0.11
2018-09-30 -0.10
2018-06-30 -0.09
2018-03-31 -0.06
2017-12-31 -0.04
2017-09-30 -0.01
2017-06-30 0.02
2017-03-31 0.02
2016-12-31 0.02
2016-09-30 0.06
2016-06-30 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Hutchison China MediTech will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Hutchison China MediTech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Hutchison China MediTech has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Hutchison China MediTech performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Hutchison China MediTech's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Hutchison China MediTech does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Hutchison China MediTech's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Hutchison China MediTech's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Hutchison China MediTech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Hutchison China MediTech Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:HNCM.F Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 213.94 -82.96 50.99
2018-12-31 214.11 -74.81 48.65
2018-09-30 215.46 -67.96 47.08
2018-06-30 216.81 -61.11 45.52
2018-03-31 230.25 -39.31 44.07
2017-12-31 241.20 -26.74 43.28
2017-09-30 239.68 -6.95 42.87
2017-06-30 238.15 12.84 42.47
2017-03-31 227.11 12.27 41.02
2016-12-31 216.08 11.70 39.58
2016-09-30 199.82 37.84 50.99
2016-06-30 200.24 -8.41 37.32
2016-03-31 189.22 -21.71 33.57
2015-12-31 178.20 -35.01 29.83
2015-09-30 167.76 -80.26 12.07
2015-06-30 139.49 -65.61 14.67
2015-03-31 113.41 -50.23 15.73
2014-12-31 87.33 -34.85 16.80
2014-09-30 72.46 -20.00 18.12
2014-06-30 58.75 7.34 24.18
2014-03-31 52.36 7.61 24.47
2013-12-31 36.55 25.92 15.82
2013-09-30 37.89 10.41 26.44
2013-06-30 29.80 12.93 28.14
2013-03-31 26.09 11.90 27.60
2012-12-31 22.37 10.86 27.07
2012-09-30 97.72 6.74 60.16
2012-06-30 92.87 5.99 55.92

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Hutchison China MediTech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Hutchison China MediTech has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Hutchison China MediTech improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Hutchison China MediTech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Hutchison China MediTech has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Hutchison China MediTech's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Hutchison China MediTech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Hutchison China MediTech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Hutchison China MediTech's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Hutchison China MediTech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 12.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Hutchison China MediTech Company Filings, last reported 2 months ago.

OTCPK:HNCM.F Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 400.36 33.06 271.86
2018-12-31 412.26 27.75 300.95
2018-09-30 412.26 27.75 300.95
2018-06-30 457.85 28.82 324.44
2018-03-31 484.97 32.57 358.30
2017-12-31 484.97 32.57 358.30
2017-09-30 484.97 32.57 358.30
2017-06-30 211.50 58.44 113.93
2017-03-31 211.50 58.44 113.93
2016-12-31 204.06 57.15 104.88
2016-09-30 204.06 57.15 104.88
2016-06-30 199.17 56.94 122.54
2016-03-31 199.17 56.94 122.54
2015-12-31 102.28 63.75 32.74
2015-09-30 101.72 60.18 32.68
2015-06-30 124.06 60.46 48.83
2015-03-31 124.06 60.46 48.83
2014-12-31 97.95 62.48 51.47
2014-09-30
2014-06-30 119.67 66.12 59.43
2014-03-31 119.67 66.12 59.43
2013-12-31 104.84 58.88 46.86
2013-09-30 104.84 58.88 46.86
2013-06-30 100.65 52.11 43.80
2013-03-31 100.65 52.11 43.80
2012-12-31 82.20 50.28 30.77
2012-09-30 83.65 50.59 62.01
2012-06-30 77.92 48.93 54.37
  • Hutchison China MediTech's level of debt (6.8%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (55.3% vs 6.8% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Hutchison China MediTech has sufficient cash runway for more than 3 years based on current free cash flow.
  • Hutchison China MediTech has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 71% each year.
X
Financial health checks
We assess Hutchison China MediTech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Hutchison China MediTech has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Hutchison China MediTech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Hutchison China MediTech dividends. Estimated to be 0% next year.
If you bought $2,000 of Hutchison China MediTech shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Hutchison China MediTech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Hutchison China MediTech's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:HNCM.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.7%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:HNCM.F Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Hutchison China MediTech has not reported any payouts.
  • Unable to verify if Hutchison China MediTech's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Hutchison China MediTech's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Hutchison China MediTech has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Hutchison China MediTech's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Hutchison China MediTech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Hutchison China MediTech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Hutchison China MediTech has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Hutchison China MediTech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Christian Hogg
COMPENSATION $1,330,074
AGE 52
TENURE AS CEO 13.4 years
CEO Bio

Mr. Christian Hogg, BSc, MBA has been the Chief Executive Officer of Hutchison China MediTech Ltd., since 2006. Mr. Hogg serves as the Chief Operating Officer of Healthcare Investments of Hutchison Whampoa (China) Limited. He serves as the Chief Operating Officer of Hutchison China's Healthcare business. He joined Hutchison China in 2000, has led all aspects of the creation, implementation and management of the Hutchison China's strategy, business and listing which includes the creation of the Hutchison China's start-up businesses and the acquisition and operational integration of assets that led to the formation of its China joint ventures. He has extensive experience managing and marketing consumer products brands in North America, Europe and Asia while at Procter & Gamble. From 1989 to 1999, he served at Procter & Gamble in the U.S., China and Europe. From 1995 to 1998, he served in China as Brand Manager of the China Laundry Joint Venture business and then as Marketing Manager for Laundry and Cleaning Products, Greater China. In 1999, he served as Global Marketing Director for the 22 country. He has been an Executive Director of Hutchison China MediTech Ltd. since 2006. He serves as a Director of Hutchison Chinese Medicine Holding Limited, Hutchison BYS (Guangzhou) Holding Limited. Mr. Hogg holds a Bachelor's degree in Civil Engineering from the University of Edinburgh, Scotland and an MBA from the University of Tennessee.

CEO Compensation
  • Christian's compensation has increased whilst company is loss making.
  • Christian's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Hutchison China MediTech management team in years:

7.4
Average Tenure
55
Average Age
  • The average tenure for the Hutchison China MediTech management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Simon To

TITLE
Executive Chairman
COMPENSATION
$335K
AGE
66

Christian Hogg

TITLE
CEO & Executive Director
COMPENSATION
$1M
AGE
52
TENURE
13.4 yrs

Johnny Cheng

TITLE
CFO & Executive Director
COMPENSATION
$682K
AGE
51
TENURE
10.9 yrs

Weiguo Su

TITLE
Chief Scientific Officer
COMPENSATION
$1M
AGE
61
TENURE
7.4 yrs

Edith Shih

TITLE
Company Secretary & Non-Executive Director
COMPENSATION
$70K
AGE
66
TENURE
13.4 yrs

Mark Lee

TITLE
Senior Vice President of Corporate Finance & Development
AGE
41

Charles Nixon

TITLE
Group General Counsel
TENURE
3.4 yrs

May Wang

TITLE
Senior Vice President of Business Development & Strategic Alliances
AGE
55

Hong Chen

TITLE
Chief Commercial Officer - China
AGE
48
TENURE
1.4 yrs

Zhenping Wu

TITLE
Senior Vice President of Pharmaceutical Sciences
AGE
59
TENURE
7.4 yrs
Board of Directors Tenure

Average tenure and age of the Hutchison China MediTech board of directors in years:

2.6
Average Tenure
60.5
Average Age
  • The average tenure for the Hutchison China MediTech board of directors is less than 3 years, this suggests a new board.
Board of Directors

Simon To

TITLE
Executive Chairman
COMPENSATION
$335K
AGE
66
TENURE
13.4 yrs

Christian Hogg

TITLE
CEO & Executive Director
COMPENSATION
$1M
AGE
52
TENURE
13.4 yrs

Johnny Cheng

TITLE
CFO & Executive Director
COMPENSATION
$682K
AGE
51
TENURE
8.4 yrs

Weiguo Su

TITLE
Chief Scientific Officer
COMPENSATION
$1M
AGE
61
TENURE
2.3 yrs

Edith Shih

TITLE
Company Secretary & Non-Executive Director
COMPENSATION
$70K
AGE
66
TENURE
13.4 yrs

Paul Rutherford Carter

TITLE
Senior Independent Non-Executive Director
COMPENSATION
$113K
AGE
57
TENURE
2.3 yrs

Karen Jean Ferrante

TITLE
Independent Non-Executive Director
COMPENSATION
$103K
AGE
60
TENURE
2.3 yrs

Graeme Allan Jack

TITLE
Independent Non-Executive Director
COMPENSATION
$104K
AGE
68
TENURE
2.3 yrs

Dan Eldar

TITLE
Non-Executive Director
COMPENSATION
$70K
AGE
64
TENURE
2.8 yrs

Tony Mok

TITLE
Independent Non-Executive Director
COMPENSATION
$84K
AGE
57
TENURE
1.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Hutchison China MediTech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Hutchison China MediTech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People’s Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments. The company discovers and develops therapeutics in oncology and autoimmune diseases, as well as provides research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical stage drugs include Savolitinib, a c-MET inhibitor for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, a inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; and HMPL-523, an inhibitor for the treatment of indolent non-Hodgkin's lymphoma, as well as HMPL-689, a treatment for indolent non-Hodgkin's lymphoma and healthy volunteers. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.

Details
Name: Hutchison China MediTech Limited
HNCM.F
Exchange: OTCPK
Founded: 2000
£3,565,922,876
665,636,140
Website: http://www.chi-med.com
Address: Hutchison China MediTech Limited
Cheung Kong Center,
48th Floor,
Central,
Hong Kong
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM HCM Ordinary Shares London Stock Exchange AIM Market GB GBP 19. May 2006
OTCPK HNCM.F Ordinary Shares Pink Sheets LLC US USD 19. May 2006
DB H7T2 Ordinary Shares Deutsche Boerse AG DE EUR 19. May 2006
NasdaqGS HCM SPONSORED ADR Nasdaq Global Select US USD 18. Mar 2016
DB H7T1 SPONSORED ADR Deutsche Boerse AG DE EUR 18. Mar 2016
Number of employees
Current staff
Staff numbers
714
Hutchison China MediTech employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/17 00:12
End of day share price update: 2019/04/04 00:00
Last estimates confirmation: 2019/05/31
Last earnings filing: 2019/06/06
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.